<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01755182</url>
  </required_header>
  <id_info>
    <org_study_id>LOTUS</org_study_id>
    <secondary_id>2011-006097-76</secondary_id>
    <nct_id>NCT01755182</nct_id>
  </id_info>
  <brief_title>Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors</brief_title>
  <acronym>LOTUS</acronym>
  <official_title>Randomized Phase 3 Trial Evaluating the Efficacy of Locoregional Treatment With Transarterial Embolization (TAE) for Liver Metastases, in Combination With Pharmacotherapy, in Patients With Neuroendocrine Tumor and Inoperable Liver Metastasis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Campania &quot;Luigi Vanvitelli&quot;</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to verify if adding a locoregional treatment of liver metastasis
      (with trans-arterial embolization-TAE) to medical treatments of proven efficacy can prolong
      the progression free survival of patients affected by neuroendocrine tumors (NET) with
      inoperable liver metastases
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    difficulty enrollment, no patients received treatment
  </why_stopped>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of objective responses</measure>
    <time_frame>measured at 3 months and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in quality of life</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>worst grade adverse event per patient</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>exploratory analysis of prognostic factors</measure>
    <time_frame>3 years</time_frame>
    <description>clinical factors will be explored in relation to patient outcomes</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>Pharmacologic therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm receive systemic pharmacologic therapy alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAE and pharmacologic therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm receive systemic pharmacologic therapy and TAE</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>approved pharmacologic therapy</intervention_name>
    <arm_group_label>Pharmacologic therapy</arm_group_label>
    <arm_group_label>TAE and pharmacologic therapy</arm_group_label>
    <other_name>somatostatin analog or other medicine with proven efficacy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TAE</intervention_name>
    <description>after randomization, and after 3 months</description>
    <arm_group_label>TAE and pharmacologic therapy</arm_group_label>
    <other_name>transarterial embolization</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of NET of gastroenteropancreatic (GEP), pulmonary or unknown primary site
             origin

          -  Unresectable liver metastases, according the judgment of surgeon, (the reasons for the
             opinion of surgeon should be made explicit)

          -  Hepatic involvement ≤50% volume of the organ

          -  Radiological evidence of hepatic lesions (contemporaneous progression or appearance of
             extrahepatic lesions are allowed if not critical sites) that require change or
             initiation of systemic pharmacotherapy

          -  Patients undergoing , previously treated , or never treated with systemic medical
             therapy are eligible

          -  Patients with or without carcinoid syndrome are eligible

          -  Well (G1) or medium (G2) differentiated histology (according to WHO 2010
             classification)

          -  Ki67 ≤ 20% (G1-G2)

          -  Life expectancy &gt; 6 months

          -  Age ≥ 18 and &lt; 80 years

        Exclusion Criteria:

          -  Previous loco-regional post-surgical treatment

          -  Poorly differentiated histology

          -  Severe concomitant morbidities such as: severe coagulopathy, severe liver failure (to
             be detailed), renal failure (creatinine &gt; 2.0 mg/dl) and heart failure (NYHA 3-4 or
             unstable ischemic heart disease), contraindicating the interventional procedure or
             influencing the general prognosis (Investigator to provide details of exclusion)

          -  Extrahepatic metastasis in critical locations as: brain, spinal cord, lung with
             respiratory impairment, symptomatic vertebral lesions

          -  Patients with only extra-hepatic lesions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A Colao, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federico II University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A Faggiano, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federico II University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R D'Angelo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>F Fiore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>F Perrone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>C Gallo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MC Piccirillo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albano Laziale Ospedale &quot;Regina Apoltolorum&quot;</name>
      <address>
        <city>Albano Laziale</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Ferrara</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Genova</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>MIlano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Cardarelli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Monaldi - AORN Ospedale dei Colli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Regina Elena</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria S.M. della Misericordia di Udine</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Verona Policlinico GB Rossi</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2012</study_first_submitted>
  <study_first_submitted_qc>December 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2012</study_first_posted>
  <last_update_submitted>May 5, 2016</last_update_submitted>
  <last_update_submitted_qc>May 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>locoregional treatment</keyword>
  <keyword>liver metastases</keyword>
  <keyword>transarterial embolization</keyword>
  <keyword>upfront treatment</keyword>
  <keyword>inoperable</keyword>
  <keyword>octreotide</keyword>
  <keyword>gastroenteropancreatic (GEP)primary</keyword>
  <keyword>pulmonary primary</keyword>
  <keyword>primary unknown origin</keyword>
  <keyword>systemic therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

